Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XER-001 and SBRT in Locally-Advanced Pancreatic Adenocarcinoma
NCT07157033Phase 2Recruiting
- Sponsor
- Xerient Pharma Ltd.
- Start
- Jan 2026
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amifostine in pancreatic adenocarcinoma (PDAC), sponsored by Xerient Pharma Ltd.. Started Jan 2026; status: recruiting.
02
Drugs
amifostine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07157033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07157033.